drugset / Trial / NCT06534190
CD8 PET Imaging in Metastatic Solid Tumours
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, single-arm trial designed to evaluate the safety and imaging characteristics of 89Zr-Df-crefmirlimab in patients with locally advanced or metastatic solid tumours prior to and during PD-1 antibody therapy.
Timeline
- Start
- 2025-03-11
- Primary completion
- 2028-11
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cetrelimab | Monoclonal antibody | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |
Indications
No indication recorded.